Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer

European Journal of Cardio-thoracic Surgery

Volumn 32, Issue 3, 2007, Pages 435-439

  Matsuoka, Katsunari ^a   Sumitomo, Shinichi ^a   Nakashima, Nariyasu ^a   Nakajima, Daisuke ^a   Misaki, Noriyuki ^a  

^a JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Lung cancer; Outcomes; Surgery; Tumor markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SELECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY SURGICAL PROCEDURES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34547676038     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2007.05.014     Document Type: Article

References (21)

1. Hamada C., Tanaka F., Ohta M., Fujimura S., Kodama K., Imaizumi M., and Wada H. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncology 23 (2005) 4999-5006
2. Brundage M.D., Davies D., and Mackillop M.B. Prognostic factors in non-small cell lung cancer-a decade of progress. Chest 122 (2002) 1037-1057
3. Pujol J.L., Molinier O., Ebert W., Daures J.P., Barlesi F., Buccheri G., Paesmans M., Quoix E., Moro-Sibilot D., Szturmowicz M., Brechot J.M., Muley T., and Grenier J. CYFRA21-1 is a prognostic determinant in non-small cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 90 (2004) 2097-2105
4. Pujol J.L., Boher J.M., Grenier J., and Quantin X. Cyfra21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 31 (2001) 221-231
5. Reinmuth N., Brandt B., Semik M., Kunze W.P., Achatzy R., Scheld H.H., Broermann P., Berdel W.E., Macha H.N., and Thomas M. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 36 (2002) 265-270
6. Niklinski J., Furman M., Burzykowski T., Chyczewski L., Laudanski J., Chyczewska E., and Rapellino M. Preoperative CYFRA21-1 levels as a prognostic indicator in resected primary squamous cell lung cancer. Br J Cancer 74 (1996) 956-960
7. Brechot J.M., Chevret S., Nataf J., Le Gall C., Fretault J., Rochemaure J., and Chastang C. Diagnostic and prognostic value of Cyfra21-1 compared with other tumor markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 33 (1997) 385-391
8. Nisman B., Lafair J., Heching N., Lyass O., Baras M., Peretz T., and Barak V. Evaluation of tissue polypeptide specific antigen, CYFRA21-1, and carcinoembryonic antigen in nonsmall cell carcinoma: does the combined use of cytokeratin markers give any additional information?. Cancer 82 (1998) 1850-1859
9. Stieber P., Hasholzner U., Bodenmuller H., Nagel D., Sunder-Plassmann L., Dienemann H., Meier W., and Fateh-Moghadam A. CYFRA21-1. A new marker in lung cancer. Cancer (Phila.) 72 (1993) 707-713
10. Foa P., Fornier M., Miceli R., Seregni E., Santambrogio L., Nosotti M., Cataldo I., Sala M., Caldiera S., and Bombardieri E. Tumor markers CEA, NSE, SCC, TPA and CYFRA21-1 in resectable non-small cell lung cancer. Anticancer Res 19 (1999) 3613-3618
11. Okada M., Nishio W., Sakamoto T., Uchino K., Yuki T., Nakagawa A., and Tsubota N. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1000 consecutive resections for clinical stage I disease. Ann Thorac Surg 78 (2004) 216-221
12. Sawabata N., Ohta M., Takeda S., Hirano H., Okumura Y., Asada H., and Maeda H. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 74 (2002) 174-179
13. Hotta K., Segawa Y., Takigawa N., Kishino D., Saeki H., Nakata M., Mandai K., and Eguchi K. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer. Anticancer Res 20 (2000) 2177-2180
14. Concannon J.P., Dalbow M.H., Hodgson S.E., Headings J.J., Markopoulos E., Mitchell J., Cushing W.J., and Liebler G.A. Prognostic value of preoperative carcinoembryonic antigen (CEA) plasma levels in patients with bronchogenic carcinoma. Cancer 42 (1978) 1477-1483
15. Icard P., Regnard J.F., Essomba A., Panebianco V., Magdeleinat P., and Levasseur P. Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer. Ann Thorac Surg 58 (1994) 811-814
16. Rubins J.B., Dunitz J., Rubins H.B., Maddaus M.A., and Niewoehner D.E. Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg 116 (1998) 412-416
17. Muley T., Dienemann H., and Ebert W. CYFRA21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res 24 (2004) 1953-1956
18. Tomita M., Matsuzaki Y., Edogawa M., Shimizu T., Hara M., and Onitsuka T. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma. Ann Thorac Cardiovasc Surg 10 (2004) 76-80
19. Nisman B., Amir G., Lafair J., Heching N., Lyass O., Peretz T., and Barak V. Prognostic value of CYFRA21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 19 (1999) 3549-3552
20. Kulpa J., Wojcik E., Reinfuss M., and Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 48 (2002) 1931-1937
21. Bombardieri E., Seregni E., Bogni A., Ardit S., Belloli S., Busetto A., Caniello B., Castelli M., Cianetti A., Correale M., DeAngelis G., Gandolfo G.M., Gion M., Macchia V., Mione R., Navaglia F., Onetto M., Paganuzzi M., Pecchio F., Plebani M., Rapellino M., Ruggeri G., Vannini P., Vitelli G., and Zamperlin A. Evaluation of cytokeratin 19 serum fragments (CYFRA21-1) in patients with lung cancer: results of a multicenter trial. Int J Boil Marker 9 (1994) 89-95